BioCardia (BCDA) Competitors $2.35 +0.04 (+1.73%) Closing price 04:00 PM EasternExtended Trading$2.37 +0.02 (+0.64%) As of 04:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock BCDA vs. EGRX, GANX, RNXT, OSTX, GRCE, NBRV, PRLD, ELYM, KLRS, and AADIShould you be buying BioCardia stock or one of its competitors? The main competitors of BioCardia include Eagle Pharmaceuticals (EGRX), Gain Therapeutics (GANX), RenovoRx (RNXT), OS Therapies (OSTX), Grace Therapeutics (GRCE), Nabriva Therapeutics (NBRV), Prelude Therapeutics (PRLD), Eliem Therapeutics (ELYM), Kalaris Therapeutics (KLRS), and Aadi Bioscience (AADI). These companies are all part of the "pharmaceutical products" industry. BioCardia vs. Its Competitors Eagle Pharmaceuticals Gain Therapeutics RenovoRx OS Therapies Grace Therapeutics Nabriva Therapeutics Prelude Therapeutics Eliem Therapeutics Kalaris Therapeutics Aadi Bioscience BioCardia (NASDAQ:BCDA) and Eagle Pharmaceuticals (NASDAQ:EGRX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership, profitability and media sentiment. Which has preferable earnings & valuation, BCDA or EGRX? Eagle Pharmaceuticals has higher revenue and earnings than BioCardia. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioCardia$60K215.42-$7.95M-$2.33-1.01Eagle Pharmaceuticals$257.55M0.19$35.64MN/AN/A Do institutionals and insiders hold more shares of BCDA or EGRX? 20.6% of BioCardia shares are held by institutional investors. Comparatively, 85.4% of Eagle Pharmaceuticals shares are held by institutional investors. 20.0% of BioCardia shares are held by insiders. Comparatively, 28.9% of Eagle Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Is BCDA or EGRX more profitable? Eagle Pharmaceuticals' return on equity of 0.00% beat BioCardia's return on equity.Company Net Margins Return on Equity Return on Assets BioCardiaN/A -30,792.60% -223.06% Eagle Pharmaceuticals N/A N/A N/A Which has more risk and volatility, BCDA or EGRX? BioCardia has a beta of 0.81, indicating that its share price is 19% less volatile than the S&P 500. Comparatively, Eagle Pharmaceuticals has a beta of 0.83, indicating that its share price is 17% less volatile than the S&P 500. Does the media refer more to BCDA or EGRX? In the previous week, BioCardia had 1 more articles in the media than Eagle Pharmaceuticals. MarketBeat recorded 1 mentions for BioCardia and 0 mentions for Eagle Pharmaceuticals. BioCardia's average media sentiment score of 1.89 beat Eagle Pharmaceuticals' score of 0.00 indicating that BioCardia is being referred to more favorably in the media. Company Overall Sentiment BioCardia Very Positive Eagle Pharmaceuticals Neutral Do analysts prefer BCDA or EGRX? BioCardia currently has a consensus target price of $25.00, suggesting a potential upside of 963.83%. Given BioCardia's stronger consensus rating and higher probable upside, research analysts clearly believe BioCardia is more favorable than Eagle Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioCardia 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50Eagle Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryBioCardia and Eagle Pharmaceuticals tied by winning 7 of the 14 factors compared between the two stocks. Get BioCardia News Delivered to You Automatically Sign up to receive the latest news and ratings for BCDA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BCDA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BCDA vs. The Competition Export to ExcelMetricBioCardiaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$12.71M$3.07B$5.70B$9.51BDividend YieldN/A2.36%4.69%4.01%P/E Ratio-1.0121.0428.0720.05Price / Sales215.42284.46448.5799.42Price / CashN/A42.7636.2258.56Price / Book13.068.378.665.87Net Income-$7.95M-$55.19M$3.25B$258.55M7 Day Performance5.38%5.89%4.20%2.23%1 Month Performance4.44%17.63%10.82%12.76%1 Year Performance-20.34%5.09%34.70%19.36% BioCardia Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BCDABioCardia3.4971 of 5 stars$2.35+1.7%$25.00+963.8%-18.7%$12.71M$60K-1.0140Positive NewsEGRXEagle Pharmaceuticals2.4345 of 5 stars$3.70+0.3%N/A-31.4%$48.05M$257.55M0.00100Gap DownGANXGain Therapeutics2.3561 of 5 stars$1.58-0.3%$8.20+419.0%+55.6%$47.66M$50K-1.8420Gap UpRNXTRenovoRx2.2149 of 5 stars$1.29-0.8%$7.25+462.0%+4.8%$47.54M$40K-3.236OSTXOS Therapies2.0616 of 5 stars$1.69+3.0%$18.00+965.1%N/A$47.49MN/A-1.97N/AGap UpGRCEGrace Therapeutics2.5508 of 5 stars$3.39+0.9%$12.00+254.0%N/A$46.46MN/A-3.81N/APositive NewsNBRVNabriva TherapeuticsN/AN/AN/AN/A$45.46M$35.59M0.0070PRLDPrelude Therapeutics3.6967 of 5 stars$0.84+4.6%$4.50+434.4%-84.4%$45.45M$7M-0.50120Positive NewsELYMEliem TherapeuticsN/A$1.51+3.4%N/A-82.9%$44.93MN/A-2.859Gap DownKLRSKalaris Therapeutics0.8669 of 5 stars$2.42+1.3%N/AN/A$44.70MN/A0.00110Analyst ForecastAADIAadi Bioscience0.3745 of 5 stars$1.80-2.7%$1.67-7.4%+28.0%$44.46M$25.07M-0.7940 Related Companies and Tools Related Companies EGRX Alternatives GANX Alternatives RNXT Alternatives OSTX Alternatives GRCE Alternatives NBRV Alternatives PRLD Alternatives ELYM Alternatives KLRS Alternatives AADI Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BCDA) was last updated on 7/25/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioCardia, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioCardia With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
